ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1749

Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center

Ohoud AlAhmed1, Amanda Way 2, Shoghik akoghlanian 2, Fatima Barbar-Smiley 2, Stephanie Lemle 2, Darby MacDonald 2, Kelly Wise 2, Stacy Ardoin 2 and Vidya Sivaraman 3, 1Nationwide Children's Hospital, Columbu, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Nationwide Children's Hospital and The Ohio State University, Columbus, OH

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Eye disease, Hydroxychloroquine, Pediatric rheumatology and quality improvement, prevention

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Hydroxychloroquine (HCQ) is commonly used in the treatment of autoimmune diseases. However, its use is associated with progressive irreversible retinal damage and vision loss with an estimated overall prevalence of 7.5%. In 2016, the American Academy of Ophthalmology (AAO) published revised recommendations on eye screening for patients receiving HCQ. Only 65% of rheumatology patients receiving HCQ at Nationwide Children’s Hospital (NCH) were screened in concordance with these recommendations. We developed a quality improvement (QI) initiative aiming to increase eye screening compliance in rheumatology clinic patients receiving HCQ from 65% to 85% by December 31, 2018 and to sustain the improvement for 6 months.

Methods: Our baseline analysis included patients receiving HCQ and were followed at NCH rheumatology clinic from 1/01/2017 to 8/31/2017. We formed a multidisciplinary team of rheumatologists, ophthalmologists, a clinical pharmacist, clinic nurses, a quality data technician and administrative staff. We developed consensus eye screening guidelines with risk-level stratification based on the AAO recommendations (Figure 1). A key driver diagram was utilized to identify barriers to compliance and determine possible interventions (Figure 2).

Results: Baseline performance data included 328 patients. Monthly performance assessment included an average of 41 patients on HCQ (range 30-51) (Figure 3). We reached our target of 85% compliance in February 2019 with a shift noticed in September 2018. We identified the following barriers to compliance: 1) Lack of knowledge among providers and patients, 2) Poor accuracy of data reports to reflect the population of interest, and 3) System barriers for interventions that involve another specialty with different locations and EHR systems. Major interventions included: 1) Educating providers and patients, 2) Preparing weekly pre-visit planning (PVP) to identify at-risk patients and provide screening recommendations, 3) Collaborating with ophthalmology clinic to facilitate same day eye screening, 4) Transparent sharing of provider-level data on a monthly basis showing individual performance, and 5) Implementing order-sets of specific eye tests in the EHR system.

Conclusion: This study is the first reported QI initiative to address the compliance with the 2016 eye screening recommendations for patients on HCQ. Our QI project highlights the following conclusions: 1) The usefulness of KDD in identifying root causes and planning interventions, 2) The importance of multidisciplinary team for large QI projects that involve more than one department, 3) The role of PVP in QI projects in a busy clinic setting managing multisystem diseases, and 4) The advantage of implementing interventions such as order sets in the EHR system. Next steps will be directed at maintaining providers buy-in and recruit patient/family member in the QI team.


Figure 1

Figure 1: Consensus guidelines and risk-level-based algorithm based on the 2016 revision of the American Academy of Ophthalmology eye screening recommendations for patients receiving hydroxychloroquine.


Figure 2

Figure 2: Key Driver Diagram showing the aim, key drivers and interventions to improve compliance with eye screening recommendations for rheumatology patients receiving hydroxychloroquine.


Figure 3

Figure 3: P-chart showing compliance with eye screening recommendations for rheumatology patients receiving hydroxychloroquine -HCQ- before and after the introduction of this quality improvement project.


Disclosure: O. AlAhmed, None; A. Way, None; S. akoghlanian, None; F. Barbar-Smiley, None; S. Lemle, None; D. MacDonald, None; K. Wise, None; S. Ardoin, None; V. Sivaraman, None.

To cite this abstract in AMA style:

AlAhmed O, Way A, akoghlanian S, Barbar-Smiley F, Lemle S, MacDonald D, Wise K, Ardoin S, Sivaraman V. Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/improving-eye-screening-among-pediatric-rheumatology-patients-receiving-hydroxychloroquine-experience-of-a-quaternary-care-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-eye-screening-among-pediatric-rheumatology-patients-receiving-hydroxychloroquine-experience-of-a-quaternary-care-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology